Cargando…
Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease
The 3-hydroxyquinone derivative of the non-psychotrophic phytocannabinoid cannabigerol, so-called VCE-003.2, and some other derivatives have been recently investigated for neuroprotective properties in experimental models of Parkinson’s disease (PD) in mice. The pharmacological effects in those mode...
Autores principales: | Burgaz, Sonia, García, Concepción, Gómez-Cañas, María, Rolland, Alain, Muñoz, Eduardo, Fernández-Ruiz, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198479/ https://www.ncbi.nlm.nih.gov/pubmed/34071302 http://dx.doi.org/10.3390/molecules26113245 |
Ejemplares similares
-
Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy
por: Navarrete, Carmen, et al.
Publicado: (2018) -
VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity
por: Palomares, Belen, et al.
Publicado: (2018) -
The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways
por: del Río, Carmen, et al.
Publicado: (2016) -
Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease
por: Burgaz, Sonia, et al.
Publicado: (2019) -
Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis
por: Burgaz, Sonia, et al.
Publicado: (2021)